State Board of Pharmacy Main Operating Appropriations Bi H.B. 3		
Executive	As Passed By House	As Passed By Senate
PRXCD2 OARRS access		
R.C. 3796.32	R.C. 3796.32	
Requires PRX to allow COM's Division of Mariju which is created by the bill, to access the Ohio Reporting System (OARRS) as needed to ensure with the Medical Marijuana Control Program L	Automated Rx e compliance	No provision; see COMCD18.
Fiscal effect: Minimal cost.	Fiscal effect: Same as the Executive.	
PRXCD3 Administration of immunizations by p	harmacists, pharmacy interns, and pharmacy technicians	
		R.C. 4729.41
No provision.	No provision.	Authorizes certified pharmacy technicians and registered pharmacy technicians to administer immunizations in the same manner as pharmacy interns under current law.
No provision.	No provision.	Authorizes pharmacists, interns, and technicians to administer immunizations beginning when a child is age 5, as opposed to the current law age limit of 7.
No provision.	No provision.	Eliminates, for children under age 13, a requirement that their immunizations be prescribed (immunizations for COVID-19 and the flu do not require a prescription under current law or the amendment).
No provision.	No provision.	Requires, for each immunization administered to a child under age 18, that the pharmacist, intern, or technician inform the child's parent or legal guardian of the importance of well child visits with a pediatrician or other primary care provider, and refer patients when appropriate.
		Fiscal effect: Potential minimal annual increase in PRX compliance inspection and enforcement costs.

State Board of Pharmacy		Main Operating Appropriations Bill H.B. 33
Executive	As Passed By House	As Passed By Senate
PRXCD4 Terminal distributor license exe	emptions	
		R.C. 4729.541, conforming changes in R.C. 4729.51, 4729.55
No provision.	No provision.	Adds the following exemptions from licensure as a terminal distributor of dangerous drugs: (1) a person who possesses nitrous oxide for use as a direct ingredient in food under federal regulations or for testing or maintaining a plumbing or HVAC system; (2) a person who possesses medical oxygen, sterile water, or sterile saline for direct patient administration or for installing or maintaining home medical equipment; and (3) a person who possesses controlled substances and other dangerous drugs for dog training in conjunction with a law enforcement agency.
		Fiscal effect: Loss of 221 licenses and approximately \$82,720 in fee revenue collected biennially and credited to the Occupational Licensing and Regulatory Fund (Fund 4K90). Reduction in workload for PRX licensing and inspection staff.
PRXCD5 Repeal of office-based opioid to	reatment (OBOT) licensure	
		R.C. 4729.553, (Repealed), conforming changes in numerous other R.C. sections and Section 747.30
No provision.	No provision.	Eliminates PRX's licensure of terminal distributors of dangerous drugs with an office-based opioid treatment (OBOT) classification, which is required for facilities, clinics, and other locations providing OBOT to more than 30 patients.
		Fiscal effect: Loss of 146 licenses and approximately \$64,240 in fee revenue collected biennially and credited to the Occupational Licensing and Regulatory Fund (Fund 4K90). Reduction in workload for PRX licensing and inspection staff.

State Board of Pharmacy	Main Operating Appropriations Bill H.B. 33	
Executive	As Passed By House	As Passed By Senate
PRXCD1 Cash transfer from the Medical Marijuana Control Progr	am Fund to the Drug Database Fund	
Section: 367.10	Section: 367.10	Section: 367.10
Permits the COM Director, upon request of the PRX Director, to certify an amount needed for the operation of PRX's drug database in each fiscal year. Permits the transfer of that amount from the Medical Marijuana Control Program Fund (Fund 5YSO), used by COM, to the Drug Database Fund (Fund 5SGO), used by PRX.	Same as the Executive.	Replaces the Executive provision with a provision that permits the PRX Director, in each fiscal year, to certify to the OBM Director an amount in cash to be transferred from Fund 5SYO to Fund 5SGO, and upon Controlling Board approval, appropriates any transferred amounts. Makes technical correction to reference "Fund 5SYO" instead of "Fund 5YSO".

State Board of Pharmacy		Main Operating Appropriations Bill H.B. 33	
Executive	As Passed By House	As Passed By Senate	
Makes conforming changes throughout the Revised Code.	Same as the Executive.	Same as the Executive.	
Fiscal effect: Increases costs for COM for overseeing PRX's portion of MMCP, and simultaneously reduces costs for PRX. The executive provides funding for these purpose under Fund 5SYO ALI 800650, Medical Marijuana Control Program.	Fiscal effect: Same as the Executive.	Fiscal effect: Same as the Executive.	

State Board of Pharmacy Main Operating Appropriations E H.B.		
Executive	As Passed By House	As Passed By Senate
MEDCD2 Legacy pain management study committee	<u> </u>	
	Section: 335.20	Section: 335.20
No provision.	Establishes the Legacy Pain Management Study Commit study and evaluate the care and treatment of patients suffering from chronic or debilitating pain, in particular who have been prescribed opioids for lengthy periods often referred to as legacy patients.	those
No provision.	Includes the following as members of the committee: for members of the General Assembly, one representative OhioMHAS, one representative of SMBO, one represent of PRX, one member representing patients, and one members representing prescribers.	of tative
No provision.	Requires the committee to consider several topics relat legacy patients, including the availability of and access to management specialists in Ohio and the challenges assometh tapering opioid doses.	to pain
No provision.	Requires the committee, by December 1, 2024, to prepare and submit to the General Assembly a report of its recommendations for legislation to address the care an treatment of legacy patients.	I and the second se
	Fiscal effect: Minimal.	Fiscal effect: Same as the House.

State Board of Pharmacy		Main Operating Appropriations Bill H.B. 33
Executive	As Passed By House	As Passed By Senate
MHACD21 Mobile-based opioid use disorder treatment		
Section: 337.95	Section: 337.95	
Requires OhioMHAS to operate a pilot program during FY 2024 and FY 2025 to provide opioid use disorder treatment to individuals in underserved regions selected by OhioMHAS, using medication units that are mobile.	Same as the Executive.	No provision.
Specifies that the purpose of the program is to extend access to medication-assisted treatment to areas of the state lacking licensed opioid treatment programs and qualifying practitioners.	Same as the Executive.	No provision.
Requires OhioMHAS to ensure that the services provided in mobile medication units used in the pilot program are those specified in relevant guidance issued by the U.S. Substance Abuse and Mental Health Services Administration.	Same as the Executive.	No provision.
Requires PRX, SMBO, and NUR and any other state agency that OhioMHAS determines may be of assistance in accomplishing the pilot program's purpose to provide assistance upon request from OhioMHAS.	Same as the Executive.	No provision.
Requires OhioMHAS to develop a plan for implementing and evaluating the pilot program within 60 days of the section's effective date.	Same as the Executive.	No provision.
Requires OhioMHAS to complete a report of the findings obtained from the program within six months after the conclusion of the pilot program.	Same as the Executive.	No provision.
Earmarks \$750,000 in each fiscal year in GRF ALI 336504, Community Innovations, to operate the pilot program.	Same as the Executive.	No provision.